{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:43:52Z","timestamp":1789393432218,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07908-0","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:30:43Z","timestamp":1787211043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Thrombosis: An Indication-Stratified Systematic Review and Meta-Analysis of Treatment and Postoperative Prophylaxis"],"prefix":"10.1007","author":[{"given":"Chao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoufang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"4","key":"7908_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442.","journal-title":"Blood Adv"},{"issue":"16","key":"7908_CR2","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/jco.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin oncology: official J Am Soc Clin Oncol. 2023;41(16):3063\u201371. https:\/\/doi.org\/10.1200\/jco.23.00294.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"2","key":"7908_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146\u201353. https:\/\/doi.org\/10.1056\/NEJMoa025313.","journal-title":"N Engl J Med"},{"issue":"7","key":"7908_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"E Raskob Gary","year":"2018","unstructured":"Raskob Gary E, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378(7):615\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1711948.","journal-title":"N Engl J Med"},{"issue":"20","key":"7908_CR5","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/jco.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin oncology: official J Am Soc Clin Oncol. 2018;36(20):2017\u201323. https:\/\/doi.org\/10.1200\/jco.2018.78.8034.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"7908_CR6","doi-asserted-by":"publisher","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb haemostasis: JTH. 2020;18(2):411\u201321. https:\/\/doi.org\/10.1111\/jth.14662.","DOI":"10.1111\/jth.14662"},{"issue":"17","key":"7908_CR7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1915103.","journal-title":"N Engl J Med"},{"issue":"3","key":"7908_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/cancers14030559","volume":"14","author":"JH Kim","year":"2022","unstructured":"Kim JH, Yoo C, Seo S, Jeong JH, Ryoo B-Y, Kim K-p, et al. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers. 2022;14(3):559.","journal-title":"Cancers"},{"issue":"6","key":"7908_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.6004\/jnccn.2024.7016","volume":"22","author":"AT Cohen","year":"2024","unstructured":"Cohen AT, Dhamane AD, Liu X, Singh R, Han S, Stellhorn R, et al. Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism. J Natl Compr Cancer Network: JNCCN. 2024;22(6):397\u2013403. https:\/\/doi.org\/10.6004\/jnccn.2024.7016.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"3","key":"7908_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-0040-1718728","volume":"121","author":"A Cohen","year":"2021","unstructured":"Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. Thromb Haemost. 2021;121(3):383\u201395. https:\/\/doi.org\/10.1055\/s-0040-1718728.","journal-title":"Thromb Haemost"},{"issue":"11","key":"7908_CR11","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.mayocp.2021.04.026","volume":"96","author":"DE Houghton","year":"2021","unstructured":"Houghton DE, Vlazny DT, Casanegra AI, Brunton N, Froehling DA, Meverden RA et al. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. Mayo Clin Proc. 2021;96(11):2793\u2009\u2013\u2009805. https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.026","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"7908_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.4251\/wjgo.v11.i10.866","volume":"11","author":"A Recio-Boiles","year":"2019","unstructured":"Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, et al. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol. 2019;11(10):866\u201376. https:\/\/doi.org\/10.4251\/wjgo.v11.i10.866.","journal-title":"World J Gastrointest Oncol"},{"key":"7908_CR13","doi-asserted-by":"publisher","first-page":"101535","DOI":"10.1016\/j.gore.2024.101535","volume":"56","author":"V Diamond","year":"2024","unstructured":"Diamond V, Gerber K, Merli G, Mercier R, Shafer A, Rosenblum N. Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center. Gynecologic Oncol Rep. 2024;56:101535. https:\/\/doi.org\/10.1016\/j.gore.2024.101535.","journal-title":"Gynecologic Oncol Rep"},{"issue":"6","key":"7908_CR14","doi-asserted-by":"publisher","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","volume":"3","author":"SR Guntupalli","year":"2020","unstructured":"Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, et al. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA Netw open. 2020;3(6):e207410. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.7410.","journal-title":"JAMA Netw open"},{"key":"7908_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ygyno.2024.01.039","volume":"183","author":"A Knisely","year":"2024","unstructured":"Knisely A, Iniesta MD, Batman S, Meyer LA, Soliman PT, Cain KE, et al. Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. Gynecol Oncol. 2024;183:120\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.039.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"7908_CR16","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1097\/js9.0000000000004020","volume":"112","author":"SA Miratashi Yazdi","year":"2026","unstructured":"Miratashi Yazdi SA, Pezeshki PS, Zafarghandi MR. Apixaban versus enoxaparin for venous thromboembolism prophylaxis after total gastrectomy in patients with gastric cancer: a randomized controlled trial. Int J Surg (London England). 2026;112(2):3701\u20138. https:\/\/doi.org\/10.1097\/js9.0000000000004020.","journal-title":"Int J Surg (London England)"},{"key":"7908_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ygyno.2023.02.012","volume":"172","author":"E Sp\u00e9nard","year":"2023","unstructured":"Sp\u00e9nard E, Geerts W, Lin Y, Gien LT, Kupets R, Covens A, et al. Apixaban for extended postoperative thromboprophylaxis in gynecologic oncology patients undergoing laparotomy. Gynecol Oncol. 2023;172:9\u201314. https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.012.","journal-title":"Gynecol Oncol"},{"key":"7908_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ygyno.2024.06.013","volume":"188","author":"KT Stewart","year":"2024","unstructured":"Stewart KT, Jafari H, Pattillo J, Santos J, Jao C, Kwok K, et al. Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery. Gynecol Oncol. 2024;188:131\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2024.06.013.","journal-title":"Gynecol Oncol"},{"key":"7908_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","volume":"148","author":"M Verso","year":"2021","unstructured":"Verso M, Munoz A, Bauersachs R, Huisman MV, Mandal\u00e0 M, Vescovo G, et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J cancer (Oxford England: 1990). 2021;148:371\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.026.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"11","key":"7908_CR20","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/ajh.25604","volume":"94","author":"WE Wysokinski","year":"2019","unstructured":"Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott-Kitslaar DM, Froehling DA, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol. 2019;94(11):1185\u201392. https:\/\/doi.org\/10.1002\/ajh.25604.","journal-title":"Am J Hematol"},{"issue":"5","key":"7908_CR21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/1708538120971148","volume":"29","author":"ME Mokadem","year":"2021","unstructured":"Mokadem ME, Hassan A, Algaby AZ. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular. 2021;29(5):745\u201350. https:\/\/doi.org\/10.1177\/1708538120971148.","journal-title":"Vascular"},{"issue":"4","key":"7908_CR22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/JU.0000000000002788","volume":"208","author":"ME Westerman","year":"2022","unstructured":"Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, et al. Apixaban vs enoxaparin for post-surgical extended-duration venous thromboembolic event prophylaxis: a prospective quality improvement study. J Urol. 2022;208(4):886\u201395.","journal-title":"J Urol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07908-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07908-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:30:44Z","timestamp":1787211044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07908-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":22,"alternative-id":["7908"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07908-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}